Innate Pharma : Clinical developments continue to advance. Collaboration with Takeda terminated with no impact on our figures
>Cash position out to end-2025 - This morning, Innate Pharma published its results for H1 2024. Revenue and other income over the period was € 12.3m (vs € 40.2m) of which, i / € 8.3m stemming from its development agreements, primarily with AstraZeneca and Sanofi (vs € 27.1m in 2023 benefiting from the reception of an initial payment of € 25m from Sanofi) and ii / € 4.1m in public research funding (vs € 4.9m in 2023). Operating costs were down € 38.7m (vs € 40.6m in 20...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.